↓ Skip to main content

Dove Medical Press

Article Metrics

Clinical role of brexpiprazole in depression and schizophrenia

Overview of attention for article published in Therapeutics and Clinical Risk Management, March 2017
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (65th percentile)
  • Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

twitter
7 tweeters
facebook
1 Facebook page

Readers on

mendeley
47 Mendeley
Title
Clinical role of brexpiprazole in depression and schizophrenia
Published in
Therapeutics and Clinical Risk Management, March 2017
DOI 10.2147/tcrm.s94060
Pubmed ID
Authors

Nishant Parikh, Diana Robinson, Anita Clayton

Abstract

Brexpiprazole, a serotonin-dopamine activity modulator, is the second D2 partial agonist to come to market and has been approved for the treatment of schizophrenia and as an adjunctive treatment in major depressive disorder. With less intrinsic activity than aripiprazole at the D2 receptor and higher potency at 5-HT2A, 5-HT1A, and α1B receptors, the pharmacological properties of brexpiprazole suggest a more tolerable side effect profile with regard to akathisia, extrapyramidal dysfunction, and sedation. While no head-to-head data are currently available, double-blind placebo-controlled studies show favorable results, with the number needed to treat (NNT) vs placebo of 6-15 for response in acute schizophrenia treatment and 4 for maintenance. NNT is 12 for response and 17-31 for remission vs placebo in major depression. In schizophrenia trials, treatment-emergent adverse effects (TEAEs) and discontinuation rates due to TEAEs were lower in treatment groups vs placebo (7.1%-9.2% vs 14.7%, respectively). Meanwhile, discontinuation rates due to TEAEs in depression studies were higher in treatment groups vs placebo (1.3%-3.5% vs 0-1.4%, respectively) and appeared dose dependent. Rates of akathisia are lower compared to those with aripiprazole and cariprazine, weight gain is more prominent than with aripiprazole, cariprazine, or ziprasidone, and sedation is less than with aripiprazole but more than with cariprazine. Brexpiprazole target dosing is 2-4 mg in schizophrenia and 2 mg in depression augmentation. Dose adjustments should be considered in hepatic or renal dysfunction and/or in poor cytochrome P450 2D6 metabolizers. While brexpiprazole represents an exciting second entry for D2 partial agonists with positive studies thus far, direct head-to-head comparisons will shed more light on the efficacy and side effect profile of brexpiprazole.

Twitter Demographics

The data shown below were collected from the profiles of 7 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 47 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 13%
Student > Bachelor 5 11%
Student > Master 5 11%
Student > Postgraduate 4 9%
Other 4 9%
Other 12 26%
Unknown 11 23%
Readers by discipline Count As %
Medicine and Dentistry 15 32%
Neuroscience 6 13%
Pharmacology, Toxicology and Pharmaceutical Science 5 11%
Psychology 3 6%
Social Sciences 3 6%
Other 6 13%
Unknown 9 19%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 March 2018.
All research outputs
#3,840,780
of 13,785,324 outputs
Outputs from Therapeutics and Clinical Risk Management
#209
of 982 outputs
Outputs of similar age
#87,761
of 257,292 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#5
of 20 outputs
Altmetric has tracked 13,785,324 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 982 research outputs from this source. They receive a mean Attention Score of 4.5. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 257,292 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.